MA32323B1 - Sulfonamides n-hétérocycliques annelés avec un groupe de tête oxadiazolone, procédés pour leur préparation et leur utilisation en tant qu'agents pharmaceutiques - Google Patents
Sulfonamides n-hétérocycliques annelés avec un groupe de tête oxadiazolone, procédés pour leur préparation et leur utilisation en tant qu'agents pharmaceutiquesInfo
- Publication number
- MA32323B1 MA32323B1 MA33378A MA33378A MA32323B1 MA 32323 B1 MA32323 B1 MA 32323B1 MA 33378 A MA33378 A MA 33378A MA 33378 A MA33378 A MA 33378A MA 32323 B1 MA32323 B1 MA 32323B1
- Authority
- MA
- Morocco
- Prior art keywords
- disorders
- preparation
- sulfonamides
- heterocyclic
- oxadiazolone
- Prior art date
Links
- 238000000034 method Methods 0.000 title abstract 3
- ZVTQYRVARPYRRE-UHFFFAOYSA-N oxadiazol-4-one Chemical group O=C1CON=N1 ZVTQYRVARPYRRE-UHFFFAOYSA-N 0.000 title abstract 3
- 238000002360 preparation method Methods 0.000 title abstract 3
- 229940124530 sulfonamide Drugs 0.000 title abstract 3
- 125000000623 heterocyclic group Chemical group 0.000 title 1
- 239000008177 pharmaceutical agent Substances 0.000 title 1
- 150000003456 sulfonamides Chemical class 0.000 title 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 3
- 150000001875 compounds Chemical class 0.000 abstract 2
- 150000003839 salts Chemical class 0.000 abstract 2
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 abstract 1
- 206010022489 Insulin Resistance Diseases 0.000 abstract 1
- 239000000556 agonist Substances 0.000 abstract 1
- 210000003169 central nervous system Anatomy 0.000 abstract 1
- 230000003210 demyelinating effect Effects 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 230000000694 effects Effects 0.000 abstract 1
- 230000004129 fatty acid metabolism Effects 0.000 abstract 1
- 239000008103 glucose Substances 0.000 abstract 1
- 208000015122 neurodegenerative disease Diseases 0.000 abstract 1
- 210000001428 peripheral nervous system Anatomy 0.000 abstract 1
- 230000002265 prevention Effects 0.000 abstract 1
- 208000001072 type 2 diabetes mellitus Diseases 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing aromatic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D498/04—Ortho-condensed systems
Landscapes
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Diabetes (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Endocrinology (AREA)
- Emergency Medicine (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Abstract
La présente invention concerne des sulfonamides n-hétérocycliques annelés avec groupement de tête oxadiazolone, des procédés pour leur préparation et leur utilisation comme médicaments. La présente invention concerne des sulfonamides n-hétérocycliques annelés avec groupement de tête oxadiazolone et leurs sels physiologiquement acceptables et leurs dérivés physiologiquement fonctionnels présentant une activité agoniste ppardelta ou ppardelta et pparalpha. L'invention concerne plus précisément des composés de formule i, dans laquelle les radicaux sont tels que définis, et leurs sels physiologiquement acceptables et des procédés pour leurs préparations. Les composés sont appropriés pour le traitement et/ou la prévention de troubles du métabolisme des acides gras et de troubles dans l'utilisation du glucose ainsi que de troubles dans lesquels l'insulino-résistance est impliquée et de troubles de démyélinisation et autres troubles neurodégénératifs du système nerveux central et périphérique.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP08290572 | 2008-06-09 | ||
| PCT/EP2009/003648 WO2009149820A1 (fr) | 2008-06-09 | 2009-05-22 | Sulfonamides n-hétérocycliques annelés avec groupement de tête oxadiazolone, procédés pour leur préparation et leur utilisation comme médicaments |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MA32323B1 true MA32323B1 (fr) | 2011-05-02 |
Family
ID=40219356
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MA33378A MA32323B1 (fr) | 2008-06-09 | 2010-11-30 | Sulfonamides n-hétérocycliques annelés avec un groupe de tête oxadiazolone, procédés pour leur préparation et leur utilisation en tant qu'agents pharmaceutiques |
Country Status (19)
| Country | Link |
|---|---|
| US (2) | US8329725B2 (fr) |
| EP (1) | EP2288604B1 (fr) |
| JP (1) | JP2011523664A (fr) |
| KR (1) | KR20110023855A (fr) |
| CN (1) | CN102056921A (fr) |
| AR (1) | AR072013A1 (fr) |
| AU (1) | AU2009256982A1 (fr) |
| BR (1) | BRPI0914978A2 (fr) |
| CA (1) | CA2727373A1 (fr) |
| CL (1) | CL2009001365A1 (fr) |
| IL (1) | IL209805A0 (fr) |
| MA (1) | MA32323B1 (fr) |
| MX (1) | MX2010013264A (fr) |
| NZ (1) | NZ589694A (fr) |
| RU (1) | RU2010154279A (fr) |
| TW (1) | TW201011012A (fr) |
| UY (1) | UY31872A (fr) |
| WO (1) | WO2009149820A1 (fr) |
| ZA (1) | ZA201007679B (fr) |
Families Citing this family (23)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20100029685A1 (en) * | 2006-10-25 | 2010-02-04 | Neurosearch A/S | Oxadiazole and thiadiazole compounds and their use as nicotinic acetylcholine receptor modulators |
| US8530413B2 (en) | 2010-06-21 | 2013-09-10 | Sanofi | Heterocyclically substituted methoxyphenyl derivatives with an oxo group, processes for preparation thereof and use thereof as medicaments |
| TW201215388A (en) | 2010-07-05 | 2012-04-16 | Sanofi Sa | (2-aryloxyacetylamino)phenylpropionic acid derivatives, processes for preparation thereof and use thereof as medicaments |
| TW201221505A (en) | 2010-07-05 | 2012-06-01 | Sanofi Sa | Aryloxyalkylene-substituted hydroxyphenylhexynoic acids, process for preparation thereof and use thereof as a medicament |
| TW201215387A (en) | 2010-07-05 | 2012-04-16 | Sanofi Aventis | Spirocyclically substituted 1,3-propane dioxide derivatives, processes for preparation thereof and use thereof as a medicament |
| JP6063870B2 (ja) * | 2010-11-08 | 2017-01-18 | ライセラ・コーポレイション | ＲＯＲγ活性の阻害用のＮ−スルホニル化テトラヒドロキノリンおよび関連二環化合物および病気の治療 |
| WO2013037390A1 (fr) | 2011-09-12 | 2013-03-21 | Sanofi | Dérivés amides d'acide 6-(4-hydroxyphényl)-3-styryl-1h-pyrazolo[3,4-b]pyridine-4-carboxylique en tant qu'inhibiteurs de kinase |
| WO2013045413A1 (fr) | 2011-09-27 | 2013-04-04 | Sanofi | Dérivés d'amide d'acide 6-(4-hydroxyphényl)-3-alkyl-1h-pyrazolo[3,4-b] pyridine-4-carboxylique utilisés comme inhibiteurs de kinase |
| RU2014149136A (ru) | 2012-05-08 | 2016-07-10 | Мерк Шарп И Доум Корп. | ТЕТРАГИДРОНАФТИРИДИНОВЫЕ И РОДСТВЕННЫЕ БИЦИКЛИЧЕСКИЕ СОЕДИНЕНИЯ ДЛЯ ИНГИБИРОВАНИЯ RORγ АКТИВНОСТИ И ЛЕЧЕНИЯ ЗАБОЛЕВАНИЯ |
| WO2013169864A2 (fr) | 2012-05-08 | 2013-11-14 | Lycera Corporation | Tétrahydro[1,8]naphtyridine-sulfonamide et composés apparentés pour utilisation en tant qu'agonistes de rorγ et dans le traitement d'une maladie |
| US9663502B2 (en) | 2013-12-20 | 2017-05-30 | Lycera Corporation | 2-Acylamidomethyl and sulfonylamidomethyl benzoxazine carbamates for inhibition of RORgamma activity and the treatment of disease |
| US9809561B2 (en) | 2013-12-20 | 2017-11-07 | Merck Sharp & Dohme Corp. | Tetrahydronaphthyridine, benzoxazine, aza-benzoxazine and related bicyclic compounds for inhibition of RORgamma activity and the treatment of disease |
| US9783511B2 (en) | 2013-12-20 | 2017-10-10 | Lycera Corporation | Carbamate benzoxazine propionic acids and acid derivatives for modulation of RORgamma activity and the treatment of disease |
| MX2016010998A (es) | 2014-02-27 | 2017-03-31 | Lycera Corp | Terapia celular adoptiva que usa un agonista de receptor huérfano gamma relacionado con receptor de ácido retinoico y métodos terapéuticos relacionados. |
| JP6523337B2 (ja) | 2014-05-05 | 2019-05-29 | リセラ・コーポレイションＬｙｃｅｒａ Ｃｏｒｐｏｒａｔｉｏｎ | ＲＯＲγのアゴニストとしての使用及び疾患治療のためのベンゼンスルホンアミド及び関連化合物 |
| US9896441B2 (en) | 2014-05-05 | 2018-02-20 | Lycera Corporation | Tetrahydroquinoline sulfonamide and related compounds for use as agonists of RORγ and the treatment of disease |
| CA2975997A1 (fr) | 2015-02-11 | 2016-08-18 | Merck Sharp & Dohme Corp. | Composes pyrazole substitues utilises en tant qu'inhibiteurs de rorgammat et utilisations desdits composes |
| CA2982847A1 (fr) | 2015-05-05 | 2016-11-10 | Lycera Corporation | Sulfonamides de dihydro-2h-benzo[b][1,4]oxazine et composes apparentes destines a etre utilises comme agonistes de ror.gamma. et pour le traitement de maladies |
| HK1253734A1 (zh) | 2015-06-11 | 2019-06-28 | The Regents Of The University Of Michigan | 用作RORγ激动剂和用於治疗疾病的芳基二氢-2H-苯并[B][1，4]恶嗪磺酰胺和相关化合物 |
| CA3002850A1 (fr) | 2015-10-27 | 2017-05-04 | Merck Sharp & Dohme Corp. | Composes indazole substitues utilises en tant qu'inhibiteurs de rorgammat et utilisations associees |
| JP2018531958A (ja) | 2015-10-27 | 2018-11-01 | メルク・シャープ・アンド・ドーム・コーポレーションＭｅｒｃｋ Ｓｈａｒｐ ＆ Ｄｏｈｍｅ Ｃｏｒｐ． | ＲＯＲγＴ阻害薬としてのヘテロアリール置換安息香酸及びその使用 |
| AU2016344111A1 (en) | 2015-10-27 | 2018-05-10 | Merck Sharp & Dohme Corp. | Substituted bicyclic pyrazole compounds as RORgammaT inhibitors and uses thereof |
| CN110407721A (zh) * | 2019-08-13 | 2019-11-05 | 上海毕得医药科技有限公司 | 一种4-氰基-3-(三氟甲基)苯-1-磺酰氯的合成方法 |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1345890A1 (fr) * | 2000-11-17 | 2003-09-24 | Novo Nordisk A/S | Agonistes de glucagon/antagonistes inverses |
| DE10222034A1 (de) | 2002-05-17 | 2003-11-27 | Bayer Ag | Tetrahydroisochinolin-Derivate |
| DE10229777A1 (de) | 2002-07-03 | 2004-01-29 | Bayer Ag | Indolin-Phenylsulfonamid-Derivate |
| CA2521175A1 (fr) | 2003-04-07 | 2004-10-28 | Kalypsys, Inc. | Composes phenyle a substitution para-sulfonyle utilises en tant que modulateurs des ppar |
| DE10335450A1 (de) | 2003-08-02 | 2005-02-17 | Bayer Ag | Indolin-Sulfanilsäureamide |
| DE10335449A1 (de) | 2003-08-02 | 2005-02-17 | Bayer Healthcare Ag | Bicyclische Indolinsulfonamid-Derivate |
| KR20060134191A (ko) | 2004-04-01 | 2006-12-27 | 아벤티스 파마슈티칼스 인크. | 미엘린 탈락 질환을 치료하기 위한 ｐｐｒ 델타 효능제의용도 |
| DE602004004631D1 (de) | 2004-04-01 | 2007-03-22 | Sanofi Aventis Deutschland | Oxadiazolone, Verfahren zu ihrer Herstellung sowie ihre Verwendung als Pharmazeutika |
| US7601716B2 (en) | 2006-05-01 | 2009-10-13 | Cephalon, Inc. | Pyridopyrazines and derivatives thereof as ALK and c-Met inhibitors |
| EP1932843A1 (fr) * | 2006-12-14 | 2008-06-18 | sanofi-aventis | Dérivés de sulfonyl-phenyl-2H(1,2,4) oxadiazole-5-one, procédés de préparation de ceux-ci et leur usage sous forme de médicaments |
| WO2010007972A1 (fr) * | 2008-07-14 | 2010-01-21 | 参天製薬株式会社 | Nouveau dérivé d'indole comportant un groupe carbamoyle, un groupe uréido et un groupe oxy substitué |
| KR20110111403A (ko) * | 2009-02-05 | 2011-10-11 | 고쿠리츠 다이가쿠 호진 교토 다이가쿠 | 인돌린 유도체 |
| MX2012013196A (es) * | 2010-05-12 | 2013-03-22 | Abbvie Inc | Inhibidores de pirrolopiridina y pirrolopirimidina de cinasas. |
-
2009
- 2009-05-22 CA CA2727373A patent/CA2727373A1/fr not_active Abandoned
- 2009-05-22 CN CN2009801216405A patent/CN102056921A/zh active Pending
- 2009-05-22 NZ NZ589694A patent/NZ589694A/en not_active IP Right Cessation
- 2009-05-22 US US12/996,784 patent/US8329725B2/en not_active Expired - Fee Related
- 2009-05-22 EP EP09761383.0A patent/EP2288604B1/fr active Active
- 2009-05-22 RU RU2010154279/04A patent/RU2010154279A/ru unknown
- 2009-05-22 JP JP2011512853A patent/JP2011523664A/ja not_active Withdrawn
- 2009-05-22 MX MX2010013264A patent/MX2010013264A/es unknown
- 2009-05-22 AU AU2009256982A patent/AU2009256982A1/en not_active Abandoned
- 2009-05-22 US US12/996,692 patent/US8946212B2/en not_active Expired - Fee Related
- 2009-05-22 WO PCT/EP2009/003648 patent/WO2009149820A1/fr not_active Ceased
- 2009-05-22 KR KR1020107027641A patent/KR20110023855A/ko not_active Withdrawn
- 2009-05-22 BR BRPI0914978A patent/BRPI0914978A2/pt not_active Application Discontinuation
- 2009-06-05 TW TW098118646A patent/TW201011012A/zh unknown
- 2009-06-05 CL CL2009001365A patent/CL2009001365A1/es unknown
- 2009-06-05 AR ARP090102028A patent/AR072013A1/es unknown
- 2009-06-05 UY UY0001031872A patent/UY31872A/es not_active Application Discontinuation
-
2010
- 2010-10-27 ZA ZA2010/07679A patent/ZA201007679B/en unknown
- 2010-11-30 MA MA33378A patent/MA32323B1/fr unknown
- 2010-12-06 IL IL209805A patent/IL209805A0/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| US8329725B2 (en) | 2012-12-11 |
| MX2010013264A (es) | 2011-02-25 |
| ZA201007679B (en) | 2011-07-27 |
| US20110207738A1 (en) | 2011-08-25 |
| TW201011012A (en) | 2010-03-16 |
| US8946212B2 (en) | 2015-02-03 |
| RU2010154279A (ru) | 2012-07-20 |
| US20120122853A1 (en) | 2012-05-17 |
| CA2727373A1 (fr) | 2009-12-17 |
| CN102056921A (zh) | 2011-05-11 |
| AU2009256982A1 (en) | 2009-12-17 |
| EP2288604B1 (fr) | 2014-01-08 |
| IL209805A0 (en) | 2011-02-28 |
| JP2011523664A (ja) | 2011-08-18 |
| EP2288604A1 (fr) | 2011-03-02 |
| AR072013A1 (es) | 2010-07-28 |
| WO2009149820A1 (fr) | 2009-12-17 |
| NZ589694A (en) | 2012-05-25 |
| KR20110023855A (ko) | 2011-03-08 |
| CL2009001365A1 (es) | 2010-11-05 |
| BRPI0914978A2 (pt) | 2015-10-27 |
| UY31872A (es) | 2010-01-29 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MA32323B1 (fr) | Sulfonamides n-hétérocycliques annelés avec un groupe de tête oxadiazolone, procédés pour leur préparation et leur utilisation en tant qu'agents pharmaceutiques | |
| MA30981B1 (fr) | Derives de sulfonyl-phenyl-2h-(1,2,4)oxadiazol-5-one, procedes de preparation associes et utilisation comme medicaments | |
| MY148982A (en) | Phenyl-1,2,4-oxadiazolone derivative with phenyl group, processes for their preparation and their use as pharmaceuticals | |
| US9926299B2 (en) | Inhibitors of bruton's tyrosine kinase | |
| TN2009000138A1 (fr) | Biaryl-ether-urees | |
| MA29810B1 (fr) | 4-oxy-n-[1,3,4]-thiadiazol-2-yl-benzènesulfonamides, procédés pour leur préparation et leur utilisation en tant que produits pharmaceutiques | |
| MA29805B1 (fr) | Derives de phenyl-1.2.4-oxadiazolone, leurs procedes de preparation et leur utilisation comme produits pharmaceutiques | |
| TN2013000349A1 (fr) | Imidazo[5,1-f][1,2,4] triazines pour le traitement de troubles neurologiques | |
| MA33734B1 (fr) | N1-pyrazolospirocétone inhibitrices d'acétyl-coa carboxylase | |
| MA35191B1 (fr) | Spiro-[1,3]-oxazines et spiro-[1,4]-oxazepines en tant qu'inhibiteurs de baec1 et/ou bace2 | |
| CN112384220A (zh) | sGC刺激剂治疗线粒体障碍的用途 | |
| JP6636060B2 (ja) | 中枢神経系疾患の治療に有用なトリアゾロ−ピラジン誘導体 | |
| MA37691B1 (fr) | 5-amino[1,4]thiazines comme inhibiteurs de bace1 | |
| MA29809B1 (fr) | N-[1,3,4]-thiadiazol-2-yl-benzenesulfonamides,procedes pour leur preparation et leur utilisation en tant que produits pharmaceutiques | |
| MA27741A1 (fr) | Derives diarylcycloalkyles , procede pour leur production, et leur utilisation en tant que medicaments | |
| MA37763A1 (fr) | Difluoro-hexahydro-cyclopentaoxazinyles et difluoro-hexahydro-benzooxazinyles en tant qu'inhibiteurs de bace1 | |
| UA84203C2 (en) | Oxadiazolone derivatives as ppar delta agonists | |
| HUE032235T2 (en) | Azetidinyloxyphenylpyrrolidone compounds | |
| MA29812B1 (fr) | N-[1,3,4]-thiadiazol-2-yl-benzene sulfonamides cycliques, procedes pour leur preparation et leur utilisation en tant que substances pharmaceutiques | |
| JP2025541361A (ja) | 置換テトラヒドロピロロ－ピリジノン化合物及び医学的状態の治療におけるその使用 | |
| NO20081676L (no) | Bicykliske aryl-sulfonylsyre[1,3,4]-tiadlazol-2-yl-amlder, fremgangsmate for fremstilling derav og deres anvendelse som farmasoytika | |
| MA27738A1 (fr) | Dérivés de cycloalkyle 1,3-substitués contenant des groupes acides, principalement hétérocycliques, procédés de préparation correspondants et utilisation desdits dérivés en tant que médicaments | |
| MA35398B1 (fr) | Composés inédits utilisables en tant qu'inhibiteurs de la diacylglycérol acyltransférase | |
| US9796722B1 (en) | Hepatitis B viral assembly effectors | |
| US20220047587A1 (en) | Synergistic compositions comprising r-2-(substituted-sulfonyl)-hexahydro-pyrrolo[1,2-a]pyrazin-6(2h)-ones and s-2-(substituted-sulfonyl)-hexahydro-pyrrolo[1,2-a]pyrazin-6(2h)-ones in a non-racemic ratio |